Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) Email Format

BiotechnologyNew York, United States51-200 Employees

Synergy Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for gastrointestinal diseases. Its work centers on uroguanylin analogs, a class of GI peptides under investigation to improve efficacy, safety, and tolerability for patients living with conditions such as chronic idiopathic constipation, irritable bowel syndrome with constipation, opioid-induced constipation, and ulcerative colitis. The company aims to deliver novel treatment options for patients and healthcare providers, supported by a long-running emphasis on science and innovation. Based in New York City, with research, technical operations, and commercial offices in the Philadelphia area, Synergy has historically positioned itself as a specialty GI-focused research organization with a history spanning more than two decades. The firm operates within the biotechnology research sector and maintains a relatively small to mid-size footprint, reflecting its focus on specialized drug development activities. Recent corporate developments indicate asset-related transactions involving the company and other industry players, highlighting shifts in its strategic portfolio within the broader GI therapeutics landscape.

Get verified Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) emails free

Company overview Employee directory